TW200413324A - Enantioselective process for the preparation of both enantiomers of 10, 11-dihydro-10-hydroxy-5H-dibenzo[b,f]azepine-5-carboxamide and new crystal forms tmereof - Google Patents
Enantioselective process for the preparation of both enantiomers of 10, 11-dihydro-10-hydroxy-5H-dibenzo[b,f]azepine-5-carboxamide and new crystal forms tmereof Download PDFInfo
- Publication number
- TW200413324A TW200413324A TW092127799A TW92127799A TW200413324A TW 200413324 A TW200413324 A TW 200413324A TW 092127799 A TW092127799 A TW 092127799A TW 92127799 A TW92127799 A TW 92127799A TW 200413324 A TW200413324 A TW 200413324A
- Authority
- TW
- Taiwan
- Prior art keywords
- dihydro
- dibenzo
- hydroxy
- carboxamide
- doc
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims description 9
- BMPDWHIDQYTSHX-UHFFFAOYSA-N licarbazepine Chemical compound C1C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-UHFFFAOYSA-N 0.000 title abstract description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 125000003118 aryl group Chemical group 0.000 claims abstract description 14
- 239000001257 hydrogen Substances 0.000 claims abstract description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 11
- 206010015037 epilepsy Diseases 0.000 claims abstract description 7
- 238000009901 transfer hydrogenation reaction Methods 0.000 claims abstract description 7
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims abstract description 6
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 6
- 229910052741 iridium Inorganic materials 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 229910052703 rhodium Inorganic materials 0.000 claims abstract description 5
- 229910052707 ruthenium Inorganic materials 0.000 claims abstract description 5
- 229910052742 iron Inorganic materials 0.000 claims abstract description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 4
- 229910052759 nickel Inorganic materials 0.000 claims abstract 3
- 238000012986 modification Methods 0.000 claims description 33
- 230000004048 modification Effects 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 26
- 150000001412 amines Chemical group 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 18
- -1 fluorene dibenzoazepine-5-carboxamide Chemical compound 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 claims description 12
- 239000004793 Polystyrene Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 238000002844 melting Methods 0.000 claims description 7
- 230000008018 melting Effects 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 125000001931 aliphatic group Chemical group 0.000 claims description 5
- 229920002223 polystyrene Polymers 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000852 hydrogen donor Substances 0.000 claims description 4
- QHADMMAFBAZFTE-UHFFFAOYSA-N naphtho[2,1,8-def]quinoline Chemical compound C1=CN=C2C=CC3=CC=CC4=CC=C1C2=C43 QHADMMAFBAZFTE-UHFFFAOYSA-N 0.000 claims description 4
- 239000002689 soil Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- ZFXVFMBOFIEPII-UHFFFAOYSA-N 1h-azepine-4-carboxamide Chemical compound NC(=O)C1=CC=CNC=C1 ZFXVFMBOFIEPII-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 150000003857 carboxamides Chemical class 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- BMPDWHIDQYTSHX-AWEZNQCLSA-N (S)-MHD Chemical compound C1[C@H](O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-AWEZNQCLSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 150000001409 amidines Chemical class 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- 238000002441 X-ray diffraction Methods 0.000 claims 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims 2
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 claims 1
- WRIZWKOAYKZGHB-UHFFFAOYSA-N 5-hydroxybenzo[b][1]benzazepine-11-carboxamide Chemical compound C1=C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 WRIZWKOAYKZGHB-UHFFFAOYSA-N 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- 235000008216 herbs Nutrition 0.000 claims 1
- 150000007857 hydrazones Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 7
- 239000003054 catalyst Substances 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- JRKDKWDSUYBIQB-UHFFFAOYSA-N 7,8-dihydrobenzo[b][1]benzazepin-5-one Chemical class O=C1C=C2CCC=CC2=NC2=CC=CC=C12 JRKDKWDSUYBIQB-UHFFFAOYSA-N 0.000 abstract 1
- UVGSRARLWOYTNE-UHFFFAOYSA-N OC1=C2C=CC=CC2=NC2=CCCCC2=C1 Chemical class OC1=C2C=CC=CC2=NC2=CCCCC2=C1 UVGSRARLWOYTNE-UHFFFAOYSA-N 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 239000002253 acid Substances 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 230000005855 radiation Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 125000005605 benzo group Chemical group 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000010985 leather Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- ICBZSKCTKKUQSY-YUWZRIFDSA-N 4-[(1r,2s)-1-hydroxy-2-(methylamino)propyl]phenol;hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=C(O)C=C1 ICBZSKCTKKUQSY-YUWZRIFDSA-N 0.000 description 2
- CYSPWCARDHRYJX-UHFFFAOYSA-N 9h-fluoren-1-amine Chemical compound C12=CC=CC=C2CC2=C1C=CC=C2N CYSPWCARDHRYJX-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 125000005561 phenanthryl group Chemical group 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HQDYNFWTFJFEPR-UHFFFAOYSA-N 1,2,3,3a-tetrahydropyrene Chemical compound C1=C2CCCC(C=C3)C2=C2C3=CC=CC2=C1 HQDYNFWTFJFEPR-UHFFFAOYSA-N 0.000 description 1
- MNCMBBIFTVWHIP-UHFFFAOYSA-N 1-anthracen-9-yl-2,2,2-trifluoroethanone Chemical group C1=CC=C2C(C(=O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 MNCMBBIFTVWHIP-UHFFFAOYSA-N 0.000 description 1
- ZOIKDGVUSUIOEO-UHFFFAOYSA-N 11h-benzo[b][1]benzazepine-4-carboxamide Chemical compound N1C2=CC=CC=C2C=CC2=C1C=CC=C2C(=O)N ZOIKDGVUSUIOEO-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- GAKDXGCZVSKFTM-UHFFFAOYSA-N 1H-azepine-4-carboximidamide Chemical compound N1C=CC=C(C=C1)C(N)=N GAKDXGCZVSKFTM-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- YKHJWQHRLUVWBR-UHFFFAOYSA-N 4-hydroxybenzo[b][1]benzazepine-11-carboxamide Chemical compound C1=CC2=C(O)C=CC=C2N(C(=O)N)C2=CC=CC=C21 YKHJWQHRLUVWBR-UHFFFAOYSA-N 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- FTFHZWLNIADXOA-UHFFFAOYSA-N 9h-fluorene-4-carboxamide Chemical compound C1C2=CC=CC=C2C2=C1C=CC=C2C(=O)N FTFHZWLNIADXOA-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DONJKKVGKUOCCS-UHFFFAOYSA-N C(C)(C)C1=C(C=CC=C1)C1=CC=CC=2C3=CC=CC=C3CC1=2 Chemical compound C(C)(C)C1=C(C=CC=C1)C1=CC=CC=2C3=CC=CC=C3CC1=2 DONJKKVGKUOCCS-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229910018965 MCl2 Inorganic materials 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- IVHKZGYFKJRXBD-UHFFFAOYSA-N amino carbamate Chemical compound NOC(N)=O IVHKZGYFKJRXBD-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- XDLDASNSMGOEMX-UHFFFAOYSA-N benzene benzene Chemical compound C1=CC=CC=C1.C1=CC=CC=C1 XDLDASNSMGOEMX-UHFFFAOYSA-N 0.000 description 1
- BRGYFDGWRZGEGL-UHFFFAOYSA-N benzo[b][1]benzazepine-11-carboximidamide Chemical compound C1=CC2=CC=CC=C2N(C(=N)N)C2=CC=CC=C21 BRGYFDGWRZGEGL-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- DHCWLIOIJZJFJE-UHFFFAOYSA-L dichlororuthenium Chemical compound Cl[Ru]Cl DHCWLIOIJZJFJE-UHFFFAOYSA-L 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- YUWFEBAXEOLKSG-UHFFFAOYSA-N hexamethylbenzene Chemical compound CC1=C(C)C(C)=C(C)C(C)=C1C YUWFEBAXEOLKSG-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 238000005121 nitriding Methods 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000001944 turbinate Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
200413324 玫、發明說明: 【發明所屬之技術領域】 不發明係關於一種藉1 〇_氧基-二苯并[b,f]氮雜革之轉移 氫化製造經取代鏡像純粹10_羥基-二氫二苯并[b,f]氮雜萆 之4穎方法、新穎觸媒及由新穎方法獲得之丨〇,丨卜二氫、1 〇 — 經基-5H-二苯并[b,f]氮雜箪羧醯胺兩鏡像異構物之新穎 晶形。 、 【先前技術】 經取代二氫二苯并[b,f]氮雜革已知為該等活性劑,其可 用以預防並治療某種中樞與末梢神經系統疾病。此等化合 物為已知,有些廣泛用於治療某種人類病理狀況。例如, 5H-二苯并[b,f]氮雜革-5-羧醯胺(胺基曱酸氮雜革)已成為 癲癇處理方面之有效劑。胺基甲酸氮雜萆之類似物,ι〇,η_ 一氫-10-氧基-5H-二苯并[b,f]氮雜萆胺基曱醯胺(氧卡巴 氮雜萆,·參照,例如,德國專利2,〇11,〇8?號)顯示可比較抗: 癲癇活性,具有較胺基曱酸氮雜革更低副作用。氧卡巴氮 雜萆在哺乳動物中被代謝成為10,η-二氫q…經基_5^二 笨并[b,f]氮雜萆-5-魏li胺(參照,例如,比利時專利Μ? 〇% 號)。 【發明内容】 本發明之目的為提供一種經取代1 〇-羥基-二氫二苯并 [b,f]氮雜萆之鏡像選擇性合成法,導致高產率又可保證使 環境之生態污染降至最低,在經濟上有吸引力,例如,使 用較少步驟反應及/或加工順序供製造1〇,u_二氫羥基
O:\88\88002.DOC 200413324 -5H-二苯并[b,f]氮雜箪羧醯胺,導致大鏡像異構上純粹 目標產物以及可結晶之產物。此外,本發明之另一目的為 提供一種可大規模實施之方法,因此可用作生產方法。 出乎思料的是,本發明方法顯然符合上述目的。 因此,本發明提供一種製造式la或lb之化合物之方法
其中Ri及R2各獨立為氫、鹵素、胺基或硝基;及以及“各 獨立為氫或CrC6烷基;該方法包括減少式η化合物之步驟
其中Rl,R3&r4定義如上;在氫給予體及選自式(Ilia)、 (Illb)、(IVa)、(iVb)、(Va)、(Vb)、(Via)或(VIb)之化合物 所組成之群之运原劑存在下
(Illb),
O:\88\88002.DOC 200413324
O:\88\88002.DOC -10- 200413324
(Vlb) 其中 M為 Ru,Rh,Ir,Fe,Co 或 Ni ; L i為鼠, L2表示芳基或芳基-脂肪族殘基;
Hal為鹵素; R5為脂肪族、環脂肪族、環脂肪族-脂肪族、芳基或芳基-脂肪族殘基,在各情況下,其可鍵合至聚合物; R6及R7各獨立為脂肪族、環脂肪族、環脂肪族-脂肪族、芳 基或芳基-脂肪族殘基; 118及119各為苯基或R8及R9與接附之碳原子一起形成環己烷 或環戊烷環;及 _ R17為氫、鹵素、胺基、硝基或(^-(:6烷氧基。 關於式(IVa)、(IVb)、(Va)、(Vb)、(Via)或(Vlb)之化合物, 有與(R)或(S)-BINAP之組合。 任何式(Ilia)、(Illb)、(IVa)、(IVb)、(Va)、(Vb)、(Via)或 O:\88\88002.DOC -11 - 200413324 =Ib)、之化合物之芳香族殘基被取代或,較佳為未經取代。 :其被取代時’其可例如,經-個或多個,例如,二個或 二個殘基’例如,該等選自Ci_C成基、㈣、〇钱各、
Cl C7说氧基、C2-C8烧驢基·氧基、i素如C1或F、硝 土、虱基及CF3所組成之群者所取代。 / 脂肪族fe殘基為,例 1- 7、元基、C2-C7烯基或其次C2-C7 诀基。c2-c7烯基特別是Γ i…丁咕 疋C3_C7烯基,例如’其為2-丙烯基或 I-,2-或3-丁烯基。較佳為
炔基,其較佳為丙炔基。 7块基特別是CA 環脂肪族殘基為,例如, 基。C Γ π β # 8衣烷基或,其次,c3-c8環烯 “1=為,例如’環丙基、環丁基、環戊基、環 己基及裱庚基。以環 入土 ^ 是c3,c产说I ά 土衣庚基較佳。C3-C8環烯基特別 2/縣,較料仏2♦基及環w _2_烯-基及環己_3_烯基。 埽丞次銥己 環脂肪族_脂肪族殘基為,例如 較佳為C3-C6it烧基々&炫基_Cl-C7烧基, 芳基殘基為,例如,碳環二=為環丙”基。 或特別是適⑽員與單===,特別是苯基 或不同雜原子,如氮、t 土 /、取多具有4個相同 原子、氧原子或^子^^^為似或伟氮 單氮雜、二氮雜、三氮雜田貝雜方香族殘基為,例如」-y、 鼠雜、四翁祕 〇〇 ^ 如吡咯基、吡唑基、咪唑基、:彳㈣或單嘍-環芳基, P塞吩基,而適當6員殘基特坐基23峻基、咬喃基及 基、菲基、苯并Π,3]_㈣基。適當多環殘基為蒽 ?檐基。芳基殘基可藉例如
O:\88\88002.DOC ' 12- 200413324 NH2 > 〇H ^ S03H > CH0早取代或藉〇H或CH〇及S〇3H雙取 代0 苯基-CVC7烷基、苯基-C2-C7烯 交聯PS(J)、聚乙二醇(peg)或矽 芳基-脂肪族殘基特別為, 基或苯基-c2-c7炔基。 鹵素表示氟、氯、溴或碘。 聚合物可為聚苯乙烯(PS)、 膠殘基(Si)。其例為NH-Rb 其中R15為C(〇)(CH2)n-PS或 C^)NH(CH2)n-PS ;及 _〇_Sl(Ri8)2(CH2)nRl6,其中 4 】至 7 -, R為匸丨心烷基如乙基,及R16為ps,J,pEG4Si (可獲自 Aldrich,瑞士)。 在式(Ilia)、(Illb)、(IVa)、(IVb)、(Va)、(Vb)、(VIa)或(vib) 中,以獨立、集合或以任何組合或次組合方式較佳為下列 意義: Μ為 Ru,Rh,Ir,較佳為 Rii。 L2為異丙基曱基苯、苯、六甲基苯、菜,較佳為異丙基甲: 基苯。 1^為2-或3-或4-。比啶基、‘氯-4-苯氧基-苯基、‘苯氧基_笨 基、5 - 一(πι)乙基胺基-1-奈基、5 -石肖基-1-蔡基、2-,3- 4 -石肖 基本基、4 -乙細基苯基、4 -聯苯基、9-蒽基、2-,3 -或4 -經其 本基、曱苯基、菲、苯并[1,3]-二ρ号茂、二曱基(萘-1_基乂_ 胺、三II曱基-苯基、雙(三氟曱基)-苯基、參(三氟^曱基)_ 苯基、荔基、茈基或芘基。 R6及R7各獨立為苯基、4-曱基苯基或3,5-二曱基笨基,較佳 為笨基〇 O:\88\88002.DOC -13 - 200413324 R及R為苯基或環己基或經取代苯基,較佳為苯基。
Hal較佳為氣。 R17較佳為Η。 L1定義如上。 車乂佺氫給予體為,例如,在胺如三乙胺、DBu或其他第 一月女存在下包含2-丙醇、弘戊醇或最佳為h〇〇ch之系統。 氫、”"予亦可用作惰性溶劑,尤其是2-丙醇,最佳為 HOOCH。替代氫給予體為2_丙醇,在各種觸媒及鹼,例如' Ru[(lS,2S)f TsNCH(C6H5)CH(CA侧](枯烯)及鹼 或就地[Ru( π 枯烯)C12]2及對掌性配位體(R,R_或 S,S TsDPEN,胺基-醇)及鹼。較佳鹼為:卜Bu〇K,K〇H或 I-Pr〇K 〇 在車乂佳怨樣中,本發明提供一種製造式以或rb之化合 物之方法
HO
HO
m 該方法包括在選自上述式(IIIa)、(IIIb)、(IVa)、(ivb)、(va)^ (Vb)、(VIa)或(VIb)之化合物所組成之群之還原劑及氫給予 體存在下’還原下式ΙΓ之化合物之步驟
O:\88\88002 DOC -14- 200413324
式11及1?之化合物為已知並可如界〇-八2-01 56992號所述般 製備。 本發明進一步提供式lira及Iirb之新穎化合物
°i°
Lix, i
Ra (lira), Μ
l/ N-H 其中M,Ll5 L2, R8及R9定義如上及R5,為下式之基
O:\88\88002.DOC -15 - 200413324 其中 ri為 0, 1,2, 3, 4, 5, 6或 7 ; X為〇或S ; R1Q為聚苯乙烯;
Ru為矽膠; R12為交聯聚苯乙烯; R13為聚乙二醇; R14為Ci-C6烷基;及 _ Μ為1,2或3。 較佳為下列式(lira)或(IIIfb)之化合物,其中定 義如上:
式(lira)或(IIIfb)之化合物可以傳統方式藉式VII之化合物 O:\88\88002.DOC -16- 200413324 R\ Η R3 R9 (VII), mr,r及r9定義如上,與[MCl2(p,枯稀仏反應製備,如 實例3對M=Ru所述。 式(nia)、(mb)、(IVa)、(Ivb)、(Va)、(Vb)、(via)或(v叫 之某些化合物為己知並可如Haack等人,Angew,Ch⑽.,
Ed· Engl· 1997, 36, 285-288所述般製備。 上述氮化作用可在例如適當溶劑或稀釋劑或其混合物不 存在或慣例上存在下實施,%需反應可在室溫下用冷卻或 例如,在溫度範圍為約8〇t至反應介質之沸點,較佳為約 1 0 C至、力+2GG C下用加溫,必要時,在壓力下於惰性氣體 環境及/或無水條件下於密閉容器内進行。 氫化作用可在適當惰性溶劑,例如醚如四氫呋喃、例如 酯如醋酸乙酯,1^化溶劑如二氯曱烷、超臨界C〇2、離子液 虹腈尤其是乙腈、醯胺如二曱基曱醯胺或二曱基乙醯
胺内並在溫度為例如巧8。(:至溶劑之沸點,較佳為室溫下實-施’如實例所述。 Y 由先行技藝可知,使用Ru(II)觸媒(尤其是N〇y〇H觸媒)之 非對稱轉移氫化作用係在水不存在及在惰性氣體條件下實 施。然而,根據本發明之轉移氫化步驟可在含水溶劑系統
O:\88\88002.DOC -17- 200413324 以及惰性氣體不存在下進行。此意指反應可成功,即使所 用岭劑包含水(如藉由Kaii-Fischer滴定最多3%)亦然。 視而要而疋,式(I)之化合物可轉化成其對應式(νπι)之藥 物前驅體酯 / 丫 〇
其中 Y為未分支或分支匕弋^烷基羰基、胺基Ci-Ci8烷基羰基、 (VC8環烷基羰基、Cs-C8環烷基^{^烷基羰基、鹵代C1_CU 烷基羰基、未經取代或在芳基取代的CS_C1G芳基C1_C18烷基 羰基、未經取代或在雜芳基取代的C5_CiQ雜芳基烷基 羰基、(^-(:18烷氧基羰基;及尺1,R2, R3&R4如上所述(對於: 製造條件亦可參照£?-31-751 129號)。 本發明之另-目的為提供一種可藉上述新顆方法獲得《_ 10,11-二氫-1〇4基卻_二苯并[b,f]氮雜萆_5_羧醯胺兩鏡 像異構物之新穎晶形、包含此等新穎晶形之新穎醫藥製齊丨 、 及/或此等新穎晶形在治療疾病如癲癇或在製造適合此項一 治療之醫藥調配物之用途。 一因此,本發明亦提供10,u_二氫_10_羥基-5h_二苯并[^闳 氮雜萆-5-羧醯胺兩鏡像異構物之新穎晶形,尤其是下述作 為變型A及變型B之晶形。
O:\88\880O2.DOC '18- 200413324 變型A及變型B均非收濕者。比較於(S)-或10,11-二氫 -10-羥基-5H-二苯并[b,f]氮雜箪-5-羧醯胺之非晶形式,本 文所述之晶形顯示較佳整體穩定性。此外,藉晶化之加工 步驟,化合物之純度較非晶物質增加。 變型A可藉例如X射線粉末繞射技術、伙光譜分析及溶點 區分變型B。 晶形特別可藉其X射線粉末繞射圖案區分。χ射線粉末繞 射圖案係用繞射計取得,最好使用Cu_Kai_輻射特性化有機 化a物之固體。χ射線粉末繞射圖案特別可成功地用以測定 物貝之結日日變型。為了分別特性化(R)_與(s)_i〇,l卜二氫 經基-5H-二苯并[b,f]氮雜箪_5_羧醯胺之結晶變型A與b,在 角度範圍(2Θ)為例如2。及45。下,用保持在室溫下之物質樣 品做測定。 、,自(rhg,1:u—風-1Qm_5H·二苯并[μ]氮雜箪-5一 羧醯胺與(S)-10,u,: f 一 一 經基'5H-二苯并[b,f]氮雜萆巧_ 竣&&月女之結晶變牙j Δ — ,、疋之χ射線粉末繞射 之反射線與強度)均由表!特性化。 間(取重要線 表丄· 或(s)_i〇,1]U 二氫 萆叛酿胺之結晶變型A — —苯并[b,f]氮雜
O:\88\880O2.DOC •19- 200413324 角度(。20) d-間距(A) 相對強度(大約) 7.0 12.6 m 10.0 8,8 S 11.7 7.5 S 14.1 6.28 vs 16.9 5.24 m 18.0 4.93 m 18.8 4.73 vw 19-.4 4.58 w 20.0 4.44 w 20.3 4,37 w 21.8 4.08 w 23.1 3.84 s 23.8 3.74 m 24.2 3,67 w 25.1 3.54 w 25,4 3.51 vw 26.1 3.42 m 26,5 3.36 vw 27.3 3.26 vw 28.6 3.12 w 29.9 2.99 m 31.4 2.85 m , 33.0 2.71 w 34.2 2.62 vw 38.2 2.35 w 40,5 2.23 w 44.0 2.06 / w (vs :極強,s :強,m :中度,w :弱,vw :極弱,PXRD 係在Philips 1710粉末繞射計使用Cuka輻射進行。d-間距 (d-spacings)係自2 0使用輻射波長為1.54060 A計算i一 輻射之比為2:1。X射線管係在電壓為40kV及電-流為40 mA下操作。階梯為0.02°,實施計數時間為每一階 段2.4秒。通常,2 0值為±0·卜0.2°誤差内。d-間距之實驗誤 差因而端視尖峰位置而定。) O:\88\88002.DOC -20- 200413324 如此測定之X射線粉末繞射圖案((R)-10,ll-二氫-10-羥基 -5H-二苯并[b,f]氮雜革-5-羧醯胺與(S)-10,ll-二氫-10-羥基 -5H-二苯并[b,f]氮雜箪-5-羧醯胺之尖峰位置與強度)均由 表2特性化。
表2 : (R)-或(S)-10,ll-二氫-10-羥基-5H-二苯并[b,f]氮雜 萆-5-羧醯胺之結晶變型B 角度(。28) d-間距(A) 相對強度( 9.9 8·9 W 11.4 7.8 S 12.9 6.8 W 14.0 6、3 VS 15.B 5,59 S 17.1 5J8 VW 18.0 4.94 VW 18.9 .4.69 W. 19.8 4.47 W 20.2 4.39 W 21.5 4.13 m. 21.8 4.07 W 22.8 3.90 m 23.6 3.76 s 24.1 3.69 m 25.1 3.54 VW 26.0 3.42 w 26.5 3.36 w 27.1 3.29 w 27.8 3.21 m 29.9 2.98 w 30.8 2.90 w 31.9 2.81 m 34.5 2.60 m 35.5 2.53 w 36.9 2.43 VW 38.4 2.34 VW 44,0 2.06 w O:\88\88002.DOC .21 - 200413324 (vs:極強,s:強, .中度’ w:弱,vw:極弱:PXRD係在Philips 1 7 1 〇粉末繞射計佶H r ^ t使用Cuka輻射進行。1間距係自2 g使用 :對Cllka 2輻射之比為 CUk”輻射波長為154060A計算。Cu 2:1。X射線管係在電壓為撕及電流為—a下操作。階梯 為〇·〇2。。’實施計數時間為每—階段24秒。通常,η值為土 〇· 1-0.2决差内。1間距之實驗誤差因而端視尖峰位置而 定。) 因此,本發明提供 具有蒼考變型八之(RH〇,U-二氫-1〇_羥基_5Η_二苯并 [b,f]氮雜革-5-羧醯胺之晶形,其係藉具有d_間距在12.6, 8’8, 7·5, 6.28, 5.24, 4·93, 3·84, 3·74及 3·42 埃之粉末 X射線繞射圖 特性化,更佳的是,具有參考變型八之^卜丨^丨卜二氫-⑺一 搜基-5私二笨并[b,f]氮雜箪羧醯胺之晶形,其係藉具 有 d-間距在 12.6, 8·8, 7.5, 6.28, 5.24, 4·93, 4.58, 4.44, 4.37, 4.08, 3.84, 工74, 3·67, 3.54, 3.42, 3.12及2.71埃之粉末χ射線繞射圖特性· 化, •具有參考變型Β之(R)-i〇,ii-二氫_10-羥基二笨并 [b,f]氮雜萆-5-羧醯胺之晶形,其係藉具有間距在8 9,7 8, 6.8, 6〇, 5.59, 4.13, 3.90, 3.69, 3.29及 2.60 埃之粉末 X射線繞射圖 特性化,更佳的是,具有參考變型B之(R)-1〇, 11-二氫-10二 羥基-5H-二苯并[b,f]氮雜萆-5-羧醯胺之晶形,其係藉具 有 d-間距在 8,9, 7.8, 6.8, 6.3, 5.59, 4.69, 4,47, 4.39, 4·13, 4·07, 3·90, 3·69, 3.42, 3·36, 3.29, 2.98, 2·90 及 2·60埃之粉末 X射線繞射圖特 性化, O:\88\88002.DOC -22- 200413324 •具有茶考變型A之(S)-10,11-二氫―丨『羥基-5H-二笨并 [b,f]氮雜革—5-羧醯胺之晶形,其係藉具有d-間距在12.6, 8.8, 7_5, 6.28, 5.24, 4.93, 3.84, 3.74及 3.42 埃之粉末 X射線繞射圖 特性化,更佳的是,具有參考變型A之二氫〜1〇_ 羥基-5H-二苯并[b,f]氮雜革-5-羧醯胺之晶形,其係藉具 有 d-間距在 12.6, 8.8, 7.5, 6.28, 5·24,《93, 4.58, 4.44, 4.37, 4.08, 3.84, 3.74, 3.67, 3.54, 3.42, 3.12及2.71埃之粉末又射線繞射圖特性 化, •具有參考變型β之(S)-10,ll_二氫-10_羥基_5H_二苯并[b,f] 氮雜萆-5-羧醯胺之晶形,其係藉具有間距在8.9, 7 8, 6 & 6.3, 5.59, 4.13, 3.90, 3.69, 3.29及2.60埃之粉末X射線繞射圖特 性化’更佳的疋’具有參考變型B之二氫一 羥基-5H-二苯并[b,f]氮雜革—5-羧醯胺之晶形,其係藉具 有 d-間距在 8.9, 7.8, 6.8, 6.3, 5.59, 4.69, 4.47, 4.39, 4.13, 4.07, 3.90, 3.69, 3.42, 3.36, 3.29, 2.98, 2·90 及 2.60埃之粉末 X射線繞射圖特. 性化。 在紅外線光譜中,可看到在二個結晶變型間之若干差 異,例如,主^基吸收性之變異。例如,在($)_ 1 〇,1卜二氫 -10-羥基-5Η-二苯并[b,f]氮雜蕈羧醯胺之結晶變型β之 IR光譜中,可看到強吸收性(假定羰基吸收性)在約1657至一 165 9cm 1之間,而在(s)-l〇,i^二氫-1〇-羥基 _5H_二苯并[b,f] 氮雜萆-5-羧醯胺之結晶變型八之爪光譜中,可看到強吸收 性在約1649至1651Cm-i之間,另一在二氫_1〇-羥 基-5H-二苯并[b,f]氮雜革羧醯胺之結晶變型B2Ir光譜
O:\88\880O2.DOC -23 - 200413324 中,可看到強吸收性在約1584至1 586cm·1之間,而在 (S)-l 0,11-二氫-1 〇-羥基- 5H-二苯并[b,f]氮雜箪羧醯胺之 結晶變型A之IR光譜中,此吸收性改變成值在約1564至 1 5 6 6 c πΓ1 之間。 此外,頃發現(S)-10,ll-二氫-10-羥基二笨并[^幻氮 雜革-5 —羧醯胺之結晶變型Β具有溶點為193.0與197·〇°c之 間,尤其是溶點為194.0與196.0t之間,例如,i95 5t:。 因此,本發明亦關於具有溶點為193.〇與197.0。(:之間,尤其
是溶點為194.0與196.0°C之間,例如,195.5°C之(S)-i〇 U 二氫-10-羥基-5H-二苯并[b,f]氮雜萆-5_羧醯胺之結晶變 型〇 本發明亦關於(R)-或二氫-1〇_羥基_5H_二苯并 [b,f]氮雜苯-5-羧醯胺之新穎無水晶形,其係藉溶化焓為a] J/g與U6 J/g之間,較佳為126 ;/§與131 J/g之間,最佳為丨28 J/g與129 J/g之間特性化。 (R)-或(s)-10,ll-二氫經基.5H_二苯并[b观雜革 羧醯胺之結晶變型A可藉迅速沉澱二氫 10-經基-5H-一本开[b,f]氮雜箪_5__胺自其溶液於適當 溶劑如二氯甲烧、丙_或醇如乙醇或異丙醇内,例如= ^先加溫⑻-或(料U_二氫*膝沉二笨并[咖 雜卓-5,醯胺之鮮溶液至回流溫度,然後在 曰 而得。 「、,、口日曰 (R)-或(S)-1 0,11-二氫 _ 1 _ 美 — r工一本开[b,fi氮 羧醯胺之結晶變型B可藉相 ” 曰相十衡於適當溶劑内,例如,藉在
O:\88\88002.DOC -24- 200413324 室溫下震動12至200小時如24小時於丙酮或乙醇内自對應 結晶變型A或非晶物質獲得。獲得純粹形式6所需之時間= 視鏡像異構物及所用之特殊溶劑而定。例如,具有結晶變 型A之(S)-l〇,ii-二氫-10—經基_5H_二苯并[b,f]氮雜革j竣 醯胺可在室溫下於丙酮内低於24小時轉移成具有結晶變^ B之(SHojl二氫]〇_經基-5H_二苯并[b,f]氮雜革 胺。 _ A此外,W-或⑻-uuh二氫_10_經基_5H_二苯并[b,f]氮雜 卓-5-羧醯胺之結晶變型B可藉結晶(R)_或—二氕 -10-經基-5H-二苯并[b,f]氮雜萆_5邊醢胺自其溶液於適當 溶劑如醇如乙醇或異丙醇内,尤其是,藉加入呈曰二 /、 η 、、、口 日日 型Β之(R)-或(S)_10,U_二氫_1〇_羥基_5Η_二苯并[b,f]氮雜箪 -5-羧醯胺而得。 藉本文所述之程序’化)_與(3)_鏡像異構物之不同結晶變 型A舆B可以純粹形式獲得,即,純粹鏡像異構物係以晶形 獲得,其含有低於ιο%其他晶形,較佳為低於5%其他晶I : 更佳為低於1 %其他晶形。 因此,本發明提供 一種製備具有晶形2之(R)-或(s)-10,ll-二氳-10_羥基 •5H-二苯并[b,f]氮雜萆_5_羧醯胺之方法,其中(a)(R)_或 (SHOW-二氫_10,基_5私二苯并[b,f]氮雜革_5_缓酿胺 係根據申請專利範圍第2至4項中任一項之方法製備供式 I'a或rb之化合物之鏡像選擇性製造,及⑻具有结晶變: A或呈現非晶形式之所得產物於適當溶劑内受相平衡;
O:\88\88002.DOC -25 - 200413324 •一種製備具有晶形B之(R)-或(S)-10,ll-二氫_10·經基 5Η _本并[b,f]^雜革-5-魏酿胺之方法,其中(尺)__咬 (3)-1〇,11-二氫-10-羥基-5沁二苯并[^,£]氮雜革_5_羧醯胺 係根據申請專利範圍第2至4項中任一項之方法製備供式
Ifa或I’b之化合物之鏡像選擇性製造,及具有結晶變型a 或壬現非晶形式之所得產物於適當溶劑内溶劑化,以及 加入分別具有結晶變型B之㊉分或^卜丨^丨^二氫^…羥 基—苯并[b,f]氮雜革叛酿胺之晶體; 種製備具有晶形B之(R)-或(S)-10,ll -二氫羥基 -5H-一苯并[b,f]氮雜革羧醯胺之方法,其中具有結晶 變型A或呈現非晶形式之(幻—或^兴^^二氫^…羥基 -5H-二苯并[b,f]氮雜革_5_羧醯胺於適當溶劑内受相平衡 或結晶;及 •一種製備具有晶形B之二氫_丨…羥基 -5H-二苯并[b,f]氮雜革羧醯胺之方法,其中具有結晶 變型A或呈現非晶形式之(R>或(s)-1〇,u_二氫_丨〇_羥基 -5H-—苯并[b,f]氮雜萆-5-羧醯胺於適當溶劑内溶劑化以 及加入分別具有結晶變型]5之(11)-或0)_1〇,11_二氫_1〇一 羥基-5H-一苯并[b,f]氮雜革羧醯胺之晶體(種子)。 •本文所述之具有參考變型—二氫_丨…羥基 -5H-二苯并[b,f]氮雜萆羧醯胺之晶形包含低於5%變 型A 〇 •本文所述之具有參考變型B之(S)-l〇,l:u二氫_1〇,基 _5H一苯并[b,f]氮雜箪羧醯胺之晶形包含低於5%變 O:\88\88002.DOC -26- 200413324 s广形特別穩定,特別是晶形频視為熱力學上穩定的 Π;因此其適合作為活性成分供固態給藥形式,供固態 =蝴傷固態或液態給藥形式時之中間體(具有特 存放能力)。當存放變型叫,無法可得變型A之晶 奴。5亥穩定形式對製備藥物較佳。 另H變m變❹更佳溶解於#機物與水溶液 —口此i適於/叉劑之製備。此外,變型A可併入固雄巧 量形式如錠劑内以便具有較變型B更改良,特別是更快速 生物有效性。 本發明亦關於新穎晶形於製造醫藥製劑,包含此等新穎 晶形之新穎醫藥製劑之用途’及/或其治療癲癇之用途。當 述及包含或含有活性成分之醫藥製劑或組合物時,在不再 含有晶形之液態組合物或組合物之情況下,此亦指可使用 晶形獲得之醫藥製劑(例如,使用本文所定義之晶形蝴 所得之浸劑溶液)’即使其不再含有各個晶形(例如 盆 存在於溶液中)亦然。 …八 本發明亦特別關於具有晶形八或較佳為叫吖或 (SHO’U-二氫-1〇m_5H_二笨并[b观雜箪_5邊酿胺之 新穎晶形於製造醫藥製劑之用途,其特徵為,將具有晶形A 或B之⑻-或(SHQ,U_二氫也經基_5H_二笨并[b观曰雜革 5竣酿胺之^斤穎、晶形與一種或多種載體混合。 本I月亦關於種治療遭受疾病如癲癇之溫血動物之方 法,其特徵為,給藥一劑量可以新穎晶形之一有效治療該
O:\88\88002.DOC -27- 200413324 疾病之(R)-或(S)]〇 n 一 ^ ιη、,一 曾 革-5-羧酿m,'一^ 佩二苯并[b,f]氮雜 π要〜,療之溫血動物,亦特別包括用該等 使用新穎晶形之—制 ,,... 夕⑻衣成之製劑治療;及/或具有晶形Α或Β s ()-丨〇,11-二氫 _10_ 羥基 _511_二 羧醯胺之新穎晶开^ ^ 本开[b,fm雜卓 日^於垓項治療之用途。 為了製造醫孳乘〗添,, :〜,活性成分可以例如醫藥製劑包含有 夕里 /舌生成分—起之方4I,, 之方式使用,或與顯著量一種或多 種有機或無機、液能斗、Μ 一 禋汊夕 心或固怨醫藥上可接受載體之混合物使 用0 根據本發明之醫孳 、 w柰組合物為該等腸内,尤其是鼻内、直 腸或口服或非經腸給举w 糸至/皿血動物,尤其是人類者,其本 身含有有效劑I $、、! U 4 \,、 喊一 /成为或與顯著量之醫藥上可接受載 體一起。活性成公少令丨曰1、 類、體重、年 力學情況、欲治療疾病及給藥 W里視溫血動物之種 齡及各個病況、各個藥物動 類型而定。 【貫施方式】 以下貫例例示本發明。 細寫
aqu. dansyl ee Et EtOAc HPLC 水性 5-(二甲基胺基)—1、萘磺醯基 鏡像異構純度 乙基 醋酸乙酯 高壓液態層析術
O:\88\88002.DOC -28- 200413324
Me 曱基 NMR 核磁共振 RT 室溫 THF 四氫呋喃 Ts 曱本續酿 差示掃描量熱法(DSC) DSC調查係在 Perkin Elmer DSC 7儀器或 perkin Elmer Pyns DSC上完成。約2-4毫克藥物放入金樣品盤内,其在氮 氣下密封以防在加熱相期間之氧化。自25t至:⑺艺下施加 加熱速率為10°C/分鐘。 粉末X射線繞射法(PXRJ)^) ?乂11〇係在?1111叩1710粉末乂射線繞射計上使用(211“輻 射進行。X射線管係在電壓為40kv&電流為40mA下操作。 階梯大小為0.02 °,施加每階梯計算時間為2.4秒。 紅外線光譜術(IR) IR係在Perkin -Elmer BX II FT-IR光譜計上進行。約1毫 克藥物壓成KBr丸粒。獲得12次掃描在解析度為2cm]下。 關於多晶型物之特性化,ATR-IR係使用Greasby Speeac
Golden Gate Diamond A丁R Accessory,序號 25 85 進行。約 ι〇 ¢:克試驗物質壓入使用70cNm之ATR電池内。 實例1 : 10-氧基-10,11-二氫-二苯并[b,f]氮雜萆羧酸醯 胺鏡像選擇性轉移氫化成R㈠-10,11-二氫_1〇_經基 -5H-二苯并[b,f]氮雜萆羧酸醢胺之程序 在23°C下,將曱酸與NEt3(5:2, 328毫克:289毫克)之預混合 O:\88\88002.DOC -29- 200413324 /合液滴入1 〇-氧基-1 0,1 1-二氫-二苯并[b,f]氮雜革羧醯胺 (300 宅克,1.189毫莫耳)與 RuCl[(lR,2R)-p-TsNCH(C6H5) CH(C6H5)NH2]( 7/6-ρ-枯烯,Aldrich,瑞士)(8.8毫克,〇 〇138 毫莫耳)於CH2C12(15毫升)内之混合物中並攪拌1〇分鐘。清 澈溶液加熱至回流歷1 6小時。反應混合物冷卻至RT、用 CH2C12(20毫升)稀釋並用aqU.NaHC〇3中和。在用鹽水洗蘇 後’溶液在減壓下濃縮。殘餘物係藉閃蒸層析術在矽膠上 使用6:1 Et〇Ac-Me〇H混合物作為洗提物純化以得 11(-)-10,11-二氬-10-羥基-511-二苯并[>』]氮雜箪_5_羧醯胺 (鏡像異構純度(ee)>99%,藉HPLC在Chiracel〇D上測定,保 持時間:9.46 分鐘[α ]/ =-195.3。(乙醇)。h—NMR (400 MHz, CDCI3).7.70-7.20 (m, δ Η), 5.30 (br s, 1 Η), 5.10-4.60 (br s, 2 Η), 3.75-3.40 (m,1 H),3.20-2.90 (m,1 H),2·50 (br s,2 H)。NMR數據參考文件: Benes,J等人,J· Med· Chem. 1999, 42, 2582-2587·分子量: 254.291 實例2 ·· 10-氧基-10,11-二氫-二苯并[l3,f]氮雜萆羧酸醯 胺鏡像選擇性轉移氫化成S(+)-l〇,u_二氫_10_羥基 -5Η-一苯并[b,f]氮雜革致酸酿胺之程序 在23°C下’將曱酸與NEt3(5:2,656毫克:578毫克)之預混合 溶液以二份方式加入10-氧基-1〇,1二氫-二苯并[b,f]氮雜/ 萆-5-羧醯胺(3 00毫克,1.189毫莫耳)與1^1[(13,23)«?-丁3见11 (C6H5)CH(C6H5)NH2]( τ/6-ρ-枯烯)(11 毫克,〇 〇173 毫莫耳)於 CH2C12(15毫升)内之混合物中並攪拌1〇分鐘。然後,加入曱 酸(5 0微升)後’清澈溶液加熱至回流歷ι6小時。反應混合物 O:\88\880O2.DOC -30- 200413324 冷卻至RT、用CH2C12(20毫升)稀釋並用aqu.NaHC〇3中和。 在用鹽水洗條後’溶液在減壓下漠縮。殘餘物係藉閃蒸層 析術在矽膠上使用6: lEtOAc-Me〇H混合物作為洗提物純化 以得S( + )-l〇,U-二氫- ίο-羥基-5H-二苯并[b,f]氮雜革竣 酿胺(ee>99%,藉HPLC在Chiracel〇D上測定)。保持時 間:12.00 分鐘[〇: ]d〜]96.6。(乙醇)。kNMR (400 MHz, CDCl3):7.70-7.20 (m,8 H),5.30 (br s,1 H),5.10-4.60 (br s,2 Η),3_75-3·40 (m,1 H),3.20-2.90 (m,1 H),2·50 (bi* s,2 H)。NMR數據參考文件: 861^3,}等人,1^^么0^111.1999,42,25 82-2 5 87.分子量: 254.291 替代性製造··在23°C下,將曱酸與NEt3 (5:2,328毫克: 2 89毫克)之預混合溶液滴入1 〇-氧基_丨〇,ι 二氫-二苯并[b,f] 氮雜萆-5-羧酸醯胺(300毫克,1.189毫莫耳)與 RuCl[(lS,2S)-p-dansyl_NCH(C6H5)CH(C6H5)NH2]( 77 6-p-枯 烯)(8.5毫克,0.012毫莫耳)於CH2C12(1 5毫升)内之混合物中 並攪拌10分鐘。清澈溶液加熱至回流歷16小時。反應混合 物冷卻至RT、用CH2C12(20毫升)稀釋並用aqu,NaHC〇3中 和。在用鹽水洗滌後,溶液在減壓下濃縮。殘餘物係藉閃 蒸層析術在矽膠上使用6··1 Et〇Ac-Me〇H混合物作為洗提 物純化以得S(+)-10,:H-二氫-10-羥基-5H-二苯并[b,f]氮雜一 箪-5-竣醯胺。 實例 3 : RuCl[(lS,2S)-p-dansylNCH(C6H5)CH(C6H5)NH2] (7/ ό-ρ-枯稀)之製備 a) (S,S)-5-二甲基胺基-萘-1-磺酸(2-胺基-1,2_聯苯基-乙 O:\88\88002.DOC -31 - 200413324 基)-醯胺之製備:在〇。(:下,將4311叮1氯化物(3 18毫克,1.2 毫莫耳)於THF(2毫升)内之溶液滴入(S,S)-聯苯基乙二胺 (250毫克,1.2毫莫耳)與三乙胺(〇.5毫升)於THF内之溶液 中。在RT下攪拌1 6小時後,溶劑在真空中除去,殘餘物 溶解於二氯甲烷内(2〇毫升)。有機溶劑用NaHC〇3溶液(5 毫升)洗滌、經NhSO4乾燥及在過濾後除去溶劑。層析術 可得(S,S)-5-二甲基胺基-萘-1_續酸(2_胺基_ι,2_聯苯基· 乙基)-月女作為黃色油’其係藉乾燥於真空中結晶。 M:445.593 lH-NMR (400 MHz, CDC13):8.36 (t>7.5 Hz, 2 H)5 8.17 (dd,J=7.2,1.2 Hz,1 H),7.47 (dd,J=8.8 Hz,1 H),7.34 (dd,J=8.5 Hz,1 H), 7.24-7.16 (m,4 H),7.11 (d,J=7.5Hz,1 H),6.99-6.74 (xn,6 H),4.61 (d,J=8.5Hz,1 H),4·20 (d,J=8.5Hz,1 H),2·80 (s,6 H)。 b)RuCl[(lS,2S)f danyslNCH(C6H5)CH(C6H5)NM2]( 枯 烯)之製備·(S,S)-5-二甲基胺基-萘-]^磺酸(2-胺基_丨,2_ 聯苯基-乙基)-醯胺之(80毫克,〇1δ毫莫耳)、NEt3 (刊毫 克,0·36毫莫耳)&[RuCl2(p-枯烯)]2(55毫克,〇.〇9毫莫耳) 於2-丙醇内之溶液在80它下加熱丨小時。在除去溶劑後, 用水(2¾升)洗滌深紅色殘餘物。固體在真空中乾燥並使 用而不必進一步純化。M:7 15.34。 實例4: 二氫a㈣基_5H二苯并㈣氮雜革令
幾酸酿胺之結晶變型B 120毫克二氫,,基弧二苯并[b观雜革 賴胺之結晶變型升丙㈣,所得懸浮液係 用磁性料器㈣,在21至25t下搖動16Q小時。過濾產物 O:\88\88002.DOC -32 - 200413324 並在室溫下乾燥於 二氫-10 -經基— 5H·* B 〇 空氣中,以得白色晶體形式之 本并[b,f]氮雜萆羧醯胺之結晶變型 實例5 :
(SMH二氫基孤二苯并[b,f]氮雜革_5 羧酸醯胺之結晶變型B 120毫克(S)-10,U_二氫]〇,基抓二苯并[^]氮雜革_5 一 羧醢胺之、、、口日日又型a懸浮於丨· 〇毫升丙酮内,所得懸浮液係 用磁性攪拌器攪拌,在以至以义下搖動24小時。過濾、產物 並在室溫下乾燥於空氣中,以得白色晶體形式之(Sy1〇,n_ 一氫-10-羥基- 5H-二苯并[b,f]氮雜革羧醯胺之結晶變型 B 〇 O:\88\88002.DOC -33 -
Claims (1)
- 200413324 拾、申請專利範圍: 1 * 一種製造式la或lb之化合物之方法,HOR2 (lb) R R及R各獨立為氫、_素、胺基或頌基;及 R3及R4各獨立為氫或烷基; 該方法包括還原式II化合物之步驟其中R1,R2, R3及R4如式la或lb之化合物所定義者;在氫給 予體及選自由式(Ilia)、(Illb)、(IVa)、(lVb)、(Va)、(Vb)、 (Via)及(VIb)之化合物所組成之群之還原劑存在下O:\88\88002.DOC 200413324其中 Μ為 Ru,Rh,Ir,Fe,Co 或 Ni ; L i為氮; L2表示芳基或芳基-脂肪族殘基; Hal為鹵素; / R5為脂肪族、環脂肪族、環脂肪族-脂肪族、芳基或芳基-脂肪族殘基,在各情況下,其可鍵合至聚合物; R6及R7各獨立為脂肪族、環脂肪族、環脂肪族-脂肪族、 芳基或芳基-脂肪族殘基; O:\88\880O2.DOC .2 - R及ii各為笨基咬8 土 :¾ R及R與接一 烷或環戊烷環;及 起形成裱已 Rl7為氫、烷基、齒辛 烷氧基。 土、一烷基胺基、硝基或cvc6 厶如申請專利範圍第丨 物 万去,其係供製造式I’a或I,b化合3 ·如申請專利範圍第1項之方法 浴劑系統内進行。 其中轉移氫化步驟於含水 其中轉移氫化步驟係在惰 4·如申請專利範圍第3項之方法 性氣體不存在下進行。 5· 一種式m’a及IH’b之化合物,其中 Μ為 Ru,Rh,Ir,Fe,c〇 或 Ni ; L i為鼠; O:\88\88002.DOC 200413324 l2表示芳基或芳基-脂肪族殘基; 118及119各為苯基或R8及R9與接附之碳原子一起形成環己 烯或環戊烯環;及 R5、下式之基團 'O:\88\88002.DOC -4 - 200413324 其中 η為 〇, 1,2, 3, 4, 5, 6或 7 ; X為〇或S ; R1Q為聚苯乙稀; R11為碎膠; R12為交聯聚苯乙烯; R13為聚乙二醇; 尺14為<^-(:6烷基;及 Μ為1,2或3 ; 或其鹽。 6. 一種具有參考變型Α之(R)-l〇,ll-二氫羥基_5沁二笨 并[b,f]氮雜萆-5 —羧醯胺之晶形,其特徵在於具有d•間距 (d-spacings# 12.6, 8·δ,7.5, 6·28, 5.24, 4 93, 3 84, 3 74, 3·42埃之粉 末X射線繞射圖。 7* 一種具有參考變型Β之(R)-10,ll-二氫羥基二笨 并[b,f]氮雜革-5-羧醯胺之晶形,其特徵在於具有d-間距 在 8.9, 7.8, 6.8, 6.3, 5,59, 4.13, 3.90, 3.69, 3.29, 2.60埃之粉末 X射線 繞射圖。 8· 一種具有參考變型A之(S)-10,l卜二氫—10_羥基_5H_二笨 并[b,f]氮雜萆-5-羧醯胺之晶形,其特徵在於具有d-間距一 在 12.6, 8.8, 7.5, 6.28, 5.24, 4.93, 3.84, 3.74, 3.42 埃之粉末 X射線繞 射圖。 9. 一種具有參考變型B之(S)-10,ll-二氫40-羥基-5H-二苯 并[b,f]氮雜萆-5-鼓酿胺之晶形,其特徵在於具有間距 O:\88\88002.DOC 200413324 在 8·9, 7·8, 6.8, 6·3, 繞射圖。 5.59, 4·13, 3.90, 3.69, 3.29, 2.60埃之粉末 χ射線 10. 11. 12. 13. 14. 15. 16. 17. :種W-或⑻,二氫]〇,基-5Η_二苯綱氮雜 卓-5-羧醯胺之無水晶形’其特徵係溶化焓介於122 %盥 U6 J/g之間。 =申π專利乾圍第7項之具有參考變型B之(r)-1〇,1卜二 氫-10-羥基_5H•二苯并[b,f]氮雜萆_5_羧醯胺之晶形,其包 含低於5 %變型A。 亦申π專利Ιϋ圍第9項之具有參考變型此⑻心^卜二氮 -10-經基-5Η-二苯并[b观雜箪_5遵醒胺之晶形,其包含 低於5 %變型a。 種⑻-10,11-二氫_10_經基_5]9[_二苯并[^观雜革_5_缓 醯胺之結晶變型,其具有介於193〇與197〇。。之間之熔 種w藥組合物’其包含如中請專利範圍第6至項中至 少一項之晶形以及醫藥上可接受之載體。 種用於化療遭叉癲癇之溫血動物之醫藥組合物,其包 含如申請專利範圍第6至13項中至少―項之二氮 -10-經基-5H-二苯并[b,f]氮雜¥_5選酿胺。 一種如申料利第6至13項中至少—項之晶形之甩 途’其係用於治療癲癇。 一種如申請專利範圍第6至13項中至少一項之i〇,u_二氮 -10-羥基-5H-二苯并[b,n ϋ 施 < ^ Α 」I雜卓-5-羧醯胺之新穎晶形之 用途’其係用於製造藥齋丨, 藉由此類晶形與一種或多種 O:\88\88002.DOC ' 6 - 200413324 醫藥上可接受載體混合。 18. 一種製備具有晶形B之(R)-或(S)_1〇,n_二氫_1〇_羥基_5匕 二苯并[b,f]氮雜箪緩酿胺之方法,其中 (a) (R)-或(S)-10,ll_二氫_10_羥基_5仏二苯并氮雜革 -5-羧醯胺係根據申請專利範圍第2至4項中任—項之 方法製備,以供式ra或I,b之化合物之鏡像選擇性製 造,及 (b) 具有結晶變型A或呈現非晶形式之所得產物於適當溶 劑内受相平衡。 19. 一種製備具有晶形B之(R)-或(S)-l〇,i卜二氫-1〇_羥基乃 二苯并[b,f]氮雜革-5-羧醯胺之方法,其中 (a) (R)-或(S)-10,ll-二氫 _10-羥基二苯并[b,f]氮雜革 -5-羧酿胺係根據申請專利範圍第2至4項中任一項之 方法製備,以供式I’a或I’b之化合物之鏡像選擇性製 造,及 (b) 具有結晶變型A或呈現非晶形式之所得產物於適當溶 劑内溶解並加入分別具有結晶變型B之(R)_或 (3)-10,11-二氫_1〇-羥基-5]9[_二苯并[13,;^氮雜萆_5_羧醯 胺之晶體。 20. 一種製備具有晶形B之(R)-或(S)-10,ll-二氫-10_羥基-5H二 一笨并[b,f]氮雜箪-5,竣酿胺之方法,其中具有結晶變型a 或呈現非晶形式之(R)—或(S)-10,11-二氫·1〇-羥基二 苯并[b,f]氮雜萆-5-羧醯胺於適當溶劑内受相平衡。 21. 種製備具有日日形B之(R)-或(S)-l〇,ll -二氫_ι〇·經基 O:\88\88002.DOC 200413324 二苯并[b,f]氮雜革-5-羧醯胺之方法,其中具有結晶變型A 或呈現非晶形式之(R)-或(S)-10,ll-二氫-10▲羥基oH-二 苯并[b,f]氮雜革-5-羧醯胺於適當溶劑内溶解並加入分別 具有結晶變型B之(R)-或(S)-10,ll-二氫-10-羥基-5H-二苯 并[b,f]氮雜萆-5-羧醯胺之晶體。 O:\88\88002.DOC 200413324 柒、指定代表圖: (一) 本案指定代表圖為:(無)。 (二) 本代表圖之元件代表符號簡單說明: 捌、本案若有化學式時,請揭示最能顯示發明特徵的化學式: (無) O:\88\88002.DOC
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0223224.7A GB0223224D0 (en) | 2002-10-07 | 2002-10-07 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200413324A true TW200413324A (en) | 2004-08-01 |
Family
ID=9945425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092127799A TW200413324A (en) | 2002-10-07 | 2003-10-07 | Enantioselective process for the preparation of both enantiomers of 10, 11-dihydro-10-hydroxy-5H-dibenzo[b,f]azepine-5-carboxamide and new crystal forms tmereof |
Country Status (20)
Country | Link |
---|---|
US (1) | US20060142566A1 (zh) |
EP (1) | EP1551808A1 (zh) |
JP (1) | JP2006504710A (zh) |
KR (1) | KR20050071549A (zh) |
CN (2) | CN1703404A (zh) |
AR (1) | AR041544A1 (zh) |
AU (1) | AU2003276055B2 (zh) |
BR (1) | BR0315113A (zh) |
CA (1) | CA2501237A1 (zh) |
EC (1) | ECSP055738A (zh) |
GB (1) | GB0223224D0 (zh) |
HK (1) | HK1079790A1 (zh) |
MX (1) | MXPA05003737A (zh) |
NO (1) | NO20052244L (zh) |
PE (1) | PE20040686A1 (zh) |
PL (1) | PL376379A1 (zh) |
RU (1) | RU2005114350A (zh) |
TW (1) | TW200413324A (zh) |
WO (1) | WO2004031155A1 (zh) |
ZA (1) | ZA200502561B (zh) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0303615D0 (en) * | 2003-02-17 | 2003-03-19 | Novartis Ag | Use of organic compounds |
GB0425320D0 (en) | 2004-11-17 | 2004-12-22 | Johnson Matthey Plc | Diamines |
US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
GB0515690D0 (en) * | 2005-07-29 | 2005-09-07 | Portela & Ca Sa | Asymmetric catalytic reduction |
GB2437078A (en) | 2006-04-11 | 2007-10-17 | Portela & Ca Sa | 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives |
JP5172124B2 (ja) * | 2006-09-29 | 2013-03-27 | 関東化学株式会社 | 2位に置換基を有する光学活性キヌクリジノール類の製造方法 |
GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
WO2011045648A2 (en) * | 2009-10-12 | 2011-04-21 | Matrix Laboratories Limited | Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof |
EP2383261B1 (en) | 2010-04-23 | 2013-09-04 | Euticals GmbH | Process for the asymmetric hydrogenation of ketones |
CN102250005B (zh) * | 2010-05-19 | 2015-04-08 | 浙江九洲药物科技有限公司 | 艾利西平的制备方法 |
EP2683691B1 (en) * | 2011-03-08 | 2018-06-06 | Jubilant Life Sciences Limited | PROCESS FOR THE PREPARATION OF (S)-(+)-10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ[b,f]AZEPINE-5-CARBOXAMIDE AND ESTERS THEREOF BY ENANTIOSELECTIVE REDUCTION OF 10,11-DIHYDRO-10-OXO-5H-DIBENZ[b,f]AZEPINE-5-CARBOXAMIDE |
WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
JP2015522531A (ja) | 2012-05-07 | 2015-08-06 | セリックスビオ プライヴェート リミテッド | 神経筋疾患及び神経変性疾患の治療のための組成物及び方法 |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
EP2847169A4 (en) | 2012-05-07 | 2015-09-30 | Cellix Bio Private Ltd | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
SG11201407318UA (en) | 2012-05-10 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of metabolic syndrome |
WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
CN104603100A (zh) | 2012-05-23 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗炎症性肠病的组合物和方法 |
WO2013175359A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
US9765020B2 (en) | 2012-05-23 | 2017-09-19 | Cellix Bio Private Limited | Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
US20150232426A1 (en) | 2012-09-26 | 2015-08-20 | Ranbaxy Laboratories Limited | Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
SG11201509782TA (en) | 2013-06-04 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of diabetes and pre-diabetes |
US9029540B2 (en) * | 2013-07-01 | 2015-05-12 | Boehringer Ingelheim International Gmbh | Ruthenium catalysts and their use for asymmetric reduction of ketones |
CN103483257A (zh) * | 2013-09-06 | 2014-01-01 | 江苏同禾药业有限公司 | 一种亚氨基芪的合成方法 |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
CA2976314C (en) | 2014-09-26 | 2021-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
AU2014407862B2 (en) | 2014-09-29 | 2020-03-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
CN107108535B (zh) | 2014-10-27 | 2020-04-28 | 塞尔利克斯生物私人有限公司 | 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐 |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
JP6679616B2 (ja) | 2015-01-06 | 2020-04-22 | セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited | 炎症及び疼痛の治療のための組成物及び方法 |
EP3064490A1 (en) | 2015-03-06 | 2016-09-07 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate |
CN107033079B (zh) * | 2016-10-17 | 2020-07-28 | 扬子江药业集团北京海燕药业有限公司 | 醋酸艾司利卡西平的制备方法 |
WO2021073231A1 (zh) * | 2019-10-18 | 2021-04-22 | 浙江九洲药业股份有限公司 | 一种艾利西平的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT101732B (pt) * | 1995-06-30 | 1997-12-31 | Portela & Ca Sa | Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso |
WO2000076942A1 (fr) * | 1999-06-15 | 2000-12-21 | Rhodia Chimie | Sulfonylamides et carboxamides et leur application en catalyse asymetrique |
JP2004526706A (ja) * | 2001-02-12 | 2004-09-02 | テバ ファーマシューティカル インダストリーズ リミティド | オクスカルバゼピンの新しい結晶形態及びそれらの調製方法 |
-
2002
- 2002-10-07 GB GBGB0223224.7A patent/GB0223224D0/en not_active Ceased
-
2003
- 2003-10-06 EP EP03798930A patent/EP1551808A1/en not_active Withdrawn
- 2003-10-06 AU AU2003276055A patent/AU2003276055B2/en not_active Expired - Fee Related
- 2003-10-06 RU RU2005114350/04A patent/RU2005114350A/ru not_active Application Discontinuation
- 2003-10-06 US US10/530,617 patent/US20060142566A1/en not_active Abandoned
- 2003-10-06 CN CNA2003801013117A patent/CN1703404A/zh active Pending
- 2003-10-06 BR BR0315113-1A patent/BR0315113A/pt not_active IP Right Cessation
- 2003-10-06 CN CNA2007101126346A patent/CN101062932A/zh active Pending
- 2003-10-06 PL PL03376379A patent/PL376379A1/xx unknown
- 2003-10-06 MX MXPA05003737A patent/MXPA05003737A/es not_active Application Discontinuation
- 2003-10-06 CA CA002501237A patent/CA2501237A1/en not_active Abandoned
- 2003-10-06 JP JP2004540788A patent/JP2006504710A/ja active Pending
- 2003-10-06 WO PCT/EP2003/011034 patent/WO2004031155A1/en active Application Filing
- 2003-10-06 KR KR1020057005920A patent/KR20050071549A/ko not_active Application Discontinuation
- 2003-10-07 PE PE2003001022A patent/PE20040686A1/es not_active Application Discontinuation
- 2003-10-07 AR ARP030103648A patent/AR041544A1/es not_active Application Discontinuation
- 2003-10-07 TW TW092127799A patent/TW200413324A/zh unknown
-
2005
- 2005-03-30 ZA ZA200502561A patent/ZA200502561B/en unknown
- 2005-04-06 EC EC2005005738A patent/ECSP055738A/es unknown
- 2005-05-06 NO NO20052244A patent/NO20052244L/no not_active Application Discontinuation
- 2005-12-30 HK HK05112208.8A patent/HK1079790A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP055738A (es) | 2005-07-06 |
CN101062932A (zh) | 2007-10-31 |
CN1703404A (zh) | 2005-11-30 |
NO20052244D0 (no) | 2005-05-06 |
US20060142566A1 (en) | 2006-06-29 |
PE20040686A1 (es) | 2004-10-29 |
CA2501237A1 (en) | 2004-04-15 |
AR041544A1 (es) | 2005-05-18 |
EP1551808A1 (en) | 2005-07-13 |
RU2005114350A (ru) | 2006-01-20 |
AU2003276055A1 (en) | 2004-04-23 |
BR0315113A (pt) | 2005-08-23 |
ZA200502561B (en) | 2006-02-22 |
AU2003276055B2 (en) | 2008-01-03 |
PL376379A1 (en) | 2005-12-27 |
GB0223224D0 (en) | 2002-11-13 |
JP2006504710A (ja) | 2006-02-09 |
MXPA05003737A (es) | 2005-06-17 |
NO20052244L (no) | 2005-07-07 |
KR20050071549A (ko) | 2005-07-07 |
WO2004031155A1 (en) | 2004-04-15 |
HK1079790A1 (zh) | 2006-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200413324A (en) | Enantioselective process for the preparation of both enantiomers of 10, 11-dihydro-10-hydroxy-5H-dibenzo[b,f]azepine-5-carboxamide and new crystal forms tmereof | |
CA2837727C (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
TWI461410B (zh) | 經取代之5,6-二氫-6-苯基苯並〔f〕異喹啉-2-胺化合物類 | |
CA2785716A1 (en) | Substituted pyrrolo-aminopyrimidine compounds | |
JP4748320B2 (ja) | 環状アミン誘導体又はその塩 | |
US8815854B2 (en) | Substituted imidazopyridinyl compounds | |
PT2032575E (pt) | NOVO DERIVADO DE 1,4-DIAZA-BICICLO[3,2,2]NONIL-OXADIAZOLILO E A SUA APLICAÃO MéDICA | |
NZ544026A (en) | Phosphoric acid salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine | |
JP3429338B2 (ja) | 新規なアリールグリシンアミド誘導体及びその製造法 | |
TW201100428A (en) | Substituted indolo-piperidine compounds | |
IL202706A (en) | Quinoline Compounds Suitable for the Treatment of Disorders Responding to Modulation of Serotonin 5-HT6 Receptor | |
JP6918378B2 (ja) | CaMKII阻害剤及びその使用 | |
CA2756870A1 (en) | Substituted indolo-pyridinone compounds | |
JP2018525377A (ja) | Tnfアルファの修飾因子として有用な環状化合物 | |
CA2837268A1 (en) | Compositions and methods for modulating a kinase | |
JP3476193B2 (ja) | 置換ヘキサヒドロベンゾ〔α〕フェナンスリジン類 | |
JPH10504820A (ja) | N−置換されたフェノチアジン類の使用 | |
WO1995033455A1 (en) | Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof | |
WO2012061342A2 (en) | Substituted benzo-imidazo-pyrido-diazepine compounds | |
JP7286001B2 (ja) | 第XIa因子阻害剤としての大環状誘導体 | |
TW201100424A (en) | Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds | |
EP1219619A1 (en) | Piperidine derivatives | |
CA2756809A1 (en) | Substituted tetrahydropyrazolo-pyrido-azepin compounds | |
Pitushkin et al. | Ureas derived from camphor and fenchone reveal enantiomeric preference of human soluble epoxide hydrolase. | |
CN118026929A (zh) | 一类含二胺结构的喹啉衍生物及其制备方法和应用 |